

# Andrew J Brenner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303786/publications.pdf>

Version: 2024-02-01

32  
papers

1,284  
citations

430874

18  
h-index

414414

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of GRN1005 in Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 1567-1576.	7.0	143
2	Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 308-316.	4.1	141
3	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	7.0	130
4	Common toxicities of mammalian target of rapamycin inhibitors. <i>Targeted Oncology</i> , 2011, 6, 125-129.	3.6	105
5	Metabolomic signature of brain cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 2355-2371.	2.7	86
6	NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions. <i>Cancer Research</i> , 2014, 74, 4446-4457.	0.9	76
7	Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 416-425.	1.2	71
8	MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma. <i>Nature Communications</i> , 2018, 9, 4541.	12.8	52
9	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1341-1354.	4.1	41
10	BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells. <i>Nucleic Acids Research</i> , 2019, 47, 5086-5099.	14.5	40
11	Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. <i>Breast Cancer Research</i> , 2013, 15, R59.	5.0	37
12	Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 49-57.	2.5	34
13	Hypoxia in astrocytic tumors and implications for therapy. <i>Neurobiology of Disease</i> , 2016, 85, 227-233.	4.4	34
14	Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. <i>Scientific Reports</i> , 2019, 9, 6124.	3.3	30
15	Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. <i>Scientific Reports</i> , 2021, 11, 2306.	3.3	25
16	Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. <i>Neuro-Oncology</i> , 2018, 20, 1231-1239.	1.2	24
17	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	7.0	24
18	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	1.2	23

#	ARTICLE	IF	CITATIONS
19	KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 343-357.	2.5	20
20	VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2015, 124, 365-372.	2.9	19
21	Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 3996-4007.	7.0	17
22	Everolimus Inhibits the Progression of Ductal Carcinoma <i>in Situ</i> to Invasive Breast Cancer Via Downregulation of MMP9 Expression. <i>Clinical Cancer Research</i> , 2020, 26, 1486-1496.	7.0	16
23	FASN inhibition as a potential treatment for endocrine-resistant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 375-386.	2.5	15
24	Abstract CT153: First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640. <i>Cancer Research</i> , 2017, 77, CT153-CT153.	0.9	15
25	Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 665-669.	0.4	11
26	LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. <i>Communications Biology</i> , 2021, 4, 1235.	4.4	11
27	Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway. <i>PLoS ONE</i> , 2015, 10, e0145452.	2.5	10
28	Osteolytic calvarial lesions as initial presentation of latent neurosyphilis. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 909-910.	1.5	9
29	PELP1 promotes glioblastoma progression by enhancing Wnt/ $\beta$ -catenin signaling. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz042.	0.7	9
30	Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. <i>Acta Neuropathologica Communications</i> , 2022, 10, 32.	5.2	6
31	Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab099.	0.7	5
32	Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation. <i>Molecular Cancer Therapeutics</i> , 2015, 14, A54-A54.	4.1	4